| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 9320163 | European Urology | 2005 | 7 Pages |
Abstract
The combination of cisplatin and bcl-2 antisense ON exerts significantly greater effects on cell viability and apoptosis than either agent used alone on human RCC cells. These data indicate that inhibition of bcl-2 expression may be an attractive therapeutic strategy in RCC tumors with high bcl-2 expression.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
I. Kausch, H. Jiang, B. Thode, C. Doehn, S. Krüger, D. Jocham,